In the Asia-Pacific region, autologous and allogeneic bone marrow transplantation (BMT) in patients infected with the hepatitis B virus (HBV) may be complicated by fatal hepatic failure due to viral reactivation. Survivors may suffer from accelerated hepatitis and cirrhosis. We report the first case of hepatocellular carcinoma (HCC) after autologous BMT for mediastinal B cell lymphoma. The tumor developed rampantly during a planned pregnancy 5 years after BMT. Less than 40 cases of HCC complicating pregnancy have been reported, and outcome is invariably poor. Immunosuppression and HBV reactivation after autologous BMT, as well as immune tolerance and hormonal changes associated with pregnancy may contribute to the rapid tumor growth. Biochemical and radiological surveillance for HCC should be strengthened in HBV carriers after BMT, especially in patients with the histology of chronic liver disease, or biochemical/ virological evidence of increased HBV activity. Bone Marrow Transplantation (2002) 29, 177-179. DOI: 10.1038/sj/bmt/1703339 Keywords: autologous bone marrow transplanation; hepatitis B virus; hepatocellular carcinoma; pregnancy
The incidence of secondary malignancy is increased after bone marrow transplantation (BMT). The commonest secondary malignancy after autologous BMT is therapy-related myelodysplasia (t-MDS). 1 After allogeneic BMT, the incidence of post-transplantation lymphoma (PTLD) is also increased. 2, 3 The incidence of other common solid malignancies, including lung and breast carcinoma, increase with longer follow-up of survivors. 2 Hepatocellular carcinoma (HCC) is the second commonest malignancy in the Southern Chinese (10% population hepatitis B virus (HBV) carriers). We report the first case of aggressive HCC after autologous BMT. 
Materials and methods
Between 1991 and 2000, 159 and 525 consecutive autologous and allogeneic BMTs were performed at the Queen Mary Hospital. Among all marrow recipients, 23 autologous and 60 allogeneic cases were HBV carriers. 4 Their median age was 35 years (range 5-56 years), and they included 56 men and 27 women. The protocol for myeloablation and HBV chemoprophylaxis were according to the study protocol during the time periods. 5 HBV carriers were monitored by serial hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) and hepatitis B e antibody (anti-HBe), liver biochemistry, half-yearly alpha-fetoprotein (AFP) and ultrasound (USG), and quantitative serum circulating HBV DNA (Digene Capture II) assays, at 1-6 monthly interval. 6 The median overall survival of 83 HBV cases was 23 months, with an actuarial median follow-up of 115 months. There were 32 deaths, 10 due to conditioning toxicity and liver failure (Ͻday 100), 13 due to relapse, and eight due to graft-versus-host disease (GVHD). One patient died of aggressive HCC, during a rare planned pregnancy after autologous BMT. Among the other 647 BMT recipients, no other cases of a solid tumor developing after BMT have been detected to date.
Case history and results
A 29-year-old woman, HBsAg and HBeAg positive, presented in October 1994 with primary mediastinal B cell lymphoma, with pericardial, splenic and paraaortic involvement. She achieved partial remission with six courses of Promace-Cytabom chemotherapy (adriamycin 35 mg, etoposide 160 mg, cyclophosphamide 900 mg, cytosine arabinoside 450 mg, bleomycin 7 mg, vincristine 2 mg, methotrexate 160 mg, prednisolone 150 mg ϫ 14). Her liver function tests remained normal. A computerized tomogram (CT) scan showed normal liver size and texture, and liver biopsy was not performed. An autologous BMT was performed in September 1995 (conditioning CBV: cyclophosphamide 1.5 g/m 2 ϫ 4, BCNU 100 mg/m 2 ϫ 3, etoposide 300 mg/m 2 ϫ 3). She engrafted on day 29 with no hepatic complications. Consolidation mediastinal radiotherapy (40 Gy) was given. At 14 months she developed HBV reactivation with a flare-up of circulating HBV DNA, parencymal enzymes and AFP levels ( Figure 1) . A liver biopsy showed chronic active hepatitis. Her liver biochemistry spontaneously normalized after 6 months despite persistent stable HBV viremia (Figure 1 ). Compensated HBV liver disease developed, with splenomegaly and thrombocytopenia (60 ϫ 10 9 /l), but with normal liver USG, biochemistry and AFP levels. She had a planned pregnancy 53 months after BMT. A CT scan at 52 months and an USG at 56 months showed no space-occupying lesion. An AFP level at 57 months was 522 ng/ml (normal Ͻ20, pregnancy level Ͻ400 ng/ml). At 60 months follow-up (28 weeks gestation), she complained of abdominal fullness. An USG scan showed an 8 cm liver mass, and magnetic resonance imaging (MRI) showed bi-lobar involvement (Figure 2a) . After multidisciplinary discussion, induced vaginal delivery was performed at 32 weeks of gestation, with a soaring of the AFP to 979 200 ng/ml. A normal female infant (1.7 kg) was delivered, but the patient suffered from tumor rupture 2 days afterwards. Laparotomy showed a 15 cm tumor with multiple satellite lesions and peritoneal nodules. Histology showed undifferentiated HCC (Figure 2b) , with negative staining for estrogen and progesterone receptors (Zymed, San Franscisco, CA, USA). Suturing was performed but the patient died of hepatic failure after 2 weeks.
Discussion
We present a tragic story of a young woman who succumbed to aggressive HCC during pregnancy after autologous BMT. The triad of events is highly unusual. There has only been one report of malignancy during pregnancy after BMT, but in an allogeneic recipient. 7 Pregnancy is uncommon after autologous BMT and in the setting of chronic liver disease. The incidence of HCC is low in young women (3/100 000 per year at age below 40, Hong Kong Cancer Registry 1996) and less than 40 cases of HCC complicating pregnancy have been reported worldwide, including 12 cases in Chinese. 8 The outcome is invariably poor, with few maternal survivals. This is attributed to delayed diagnosis, estrogen stimulation of HCC growth and preg- nancy-related immunotolerance. 8 Abdominal distension and raised AFP levels during pregnancy can cause diagnostic difficulty. 9 Estrogen stimulation of HCC growth is probably not a factor in our case with negative receptor staining. 10 However, caution may still be needed in advising on hormone replacement therapy in female HBV carriers after BMT.
The risks of HCC increase exponentially with cirrhosisrelated liver cell death and regeneration. 11 Chemotherapy and immunosuppression both facilitate viral replication and HBV-related liver diseases. 12 Hepatic GVHD, drug toxicity and veno-occlusive disease cause further direct liver damage, 13, 14 and accelerated cirrhosis and HCC in hepatitis C carriers have been reported. 15 In HBV carriers, the incidence of significant viral reactivation ranges from 15% for autologous BMT to 85% for allogeneic BMT between HBV positive donor-recipient pairs. 4 This incidence is reduced by pre-emptive viral suppression with HBV DNA monitoring. 12 However, with acquired resistance to purine analogues, the eventual incidence of cirrhosis and HCC may still be high. On the other hand, after allogeneic BMT from HLA matched siblings with naturally acquired immunity against HBV, clearance of HBV by adoptive immunotransfer with improvement in liver histology can occur. 16 Long-term hepatic morbidity has to be considered in donor choice. 17 Finally, since resectable early HCC is often detected in renal transplant recipients, increased screening after BMT may also be needed, 18 especially in the setting of chronic active hepatitis and persistent viremia.
